| American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients |
124 |
| American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia |
86 |
| American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy |
72 |
| American Society of Hematology 2019 guidelines for immune thrombocytopenia |
71 |
| Updated international consensus report on the investigation and management of primary immune thrombocytopenia |
65 |
| American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy |
55 |
| American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism |
51 |
| American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism |
43 |
| American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients |
41 |
| Epidemiology of AL amyloidosis: a real-world study using US claims data |
41 |
| Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib |
37 |
| Clinical consequences of clonal hematopoiesis of indeterminate potential |
35 |
| Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity |
32 |
| Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis |
30 |
| Evaluating measurable residual disease in acute myeloid leukemia |
30 |
| Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections |
29 |
| Pharmacologic control of CAR-T cell function using dasatinib |
29 |
| Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation |
27 |
| First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia |
27 |
| Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis |
26 |
| Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies |
24 |
| Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia |
24 |
| A CD123-targeting antibody-drug conjugate, IMGN designed to eradicate AML while sparing normal bone marrow cells |
23 |
| 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS |
22 |
| Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia |
21 |
| Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort |
20 |
| PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL |
20 |
| Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission |
20 |
| Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation |
20 |
| Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia |
20 |
| Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity |
19 |
| Single-cell heterogeneity in Sezary syndrome |
19 |
| Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs |
19 |
| TCF1 expression marks self-renewing human CD8(+) T cells |
19 |
| Venetoclax for AML: changing the treatment paradigm |
19 |
| ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants |
18 |
| Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion |
18 |
| Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis |
18 |
| Significant gynecological bleeding in women with low von Willebrand factor levels |
18 |
| Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies |
17 |
| T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma |
17 |
| Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide |
17 |
| Targeted next-generation sequencing in blast phase myeloproliferative neoplasms |
17 |
| Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial |
17 |
| No free rides: management of toxicities of novel immunotherapies in ALL, including financial |
17 |
| A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations |
17 |
| Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment |
16 |
| The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles |
16 |
| Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K delta inhibitors and VIP antagonists |
15 |
| Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation |
15 |
